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According to the Centers for Disease Control and Prevention (2020), traumatic 
brain injury (TBI) is considered a major public health problem in the United States. Each 
year, 2.53 million Americans, including 812,000 children, document a TBI-related 
emergency room visit (CDC, 2020). TBI is a disruption in the brain’s normal function, 
caused by a bump or blow to the head or by penetrating head injury (CDC, 2020). These 
injuries range in severity and can cause damage to one or multiple areas of the brain 
(Oleksii et al., 2019). Mild TBI, often used synonymously with concussion, comprises 
more than 90% of TBI cases (Pitkänen et al., 2020). Additionally, secondary TBI 
processes can result in several long-term neurological disabilities (Webster et al., 2017). 
Post-Traumatic Epilepsy (PTE) is defined as a recurrent seizure disorder secondary to 
trauma to the brain and has been described as one of the most devastating complications 
associated with TBI, as it can lead to neurodegenerative and neurocognitive symptoms 
(Keith & Huang, 2019). Most cases of PTE are resistant to existing anti-epileptic drugs, 
making treatment extremely difficult (Webster et al., 2017).   
The objective of this review is to explore the relationship between TBI and the 
development of PTE. A review of relevant literature from peer-reviewed publications, 
was focused on TBI, development of PTE, and potential diagnostic biomarkers for these 
conditions. It was found that elements of the neuroinflammatory response, including 
reactive astrogliosis and pro-inflammatory cytokines, may offer valuable insight into the 
development of PTE. Further research is needed to establish causal relationships, identify 






The Centers for Disease Control and Prevention (2020) defines traumatic brain 
injury (TBI) as a disruption in the brain’s normal function, caused by a bump or blow to 
the head or by penetrating head injury. These injuries can be caused by various events, 
which determine the characteristics and severity (CDC, 2020). Secondary processes 
related to TBI can result in short or long-term neurological disabilities, including post-
traumatic epilepsy (PTE) (Webster et al., 2017). While the exact relationship between 
TBI and PTE remains unknown, various pathophysiological processes may be involved. 
Furthermore, there is currently no definitive test to evaluate TBI patients to determine the 
neurological conditions that may arise (Mahan et al., 2019). Characterizing the damage 
caused by mild TBI is also challenging, given the subjectivity of diagnosis (Meier et al., 
2020). Research suggests the utilization of biomarkers associated with neurological 
damage as a means of diagnosing patients presenting with head trauma (Thelin et al., 
2019). These biomarkers may also give insight into the secondary physiological 
processes occurring after injury (Thelin et al., 2019). Understanding the pathogenesis of 
PTE is the foundation for developing and evaluating therapeutic interventions. This 
review will focus on the neuropathophysiological mechanisms of PTE following TBI and 











TBI is a global public health problem, as approximately 50 million people 
worldwide sustain TBI every year (Maas et al., 2017). As the leading cause of death and 
disability across all ages in all countries, it is predicted that nearly half the world’s 
population will sustain at least one TBI in their lifetime (Maas et al., 2017). In the United 
States, 2.87 million TBI-related emergency department visits, hospitalizations, and deaths 
were documented in 2014 (CDC, 2020). This estimate includes the 812,000 children 
treated in emergency departments for concussion or TBI alone and TBI along with other 
injuries (CDC, 2020). While age-adjusted rates for TBI-related hospitalizations and 
deaths decreased between 2006 and 2014, rates of emergency department visits increased 
by 54% and continue to rise (CDC, 2020).  
Risk factors 
Among the risk factors for TBI, age plays a large role. Rates of ED visits are 
highest for people over the age of 75 years old and for children younger than four years 
old (CDC, 2020). Accounting for nearly half of TBI-related ED visits, falls 
disproportionately affect children and older adults (CDC, 2020). Following falls, motor 
vehicle accidents were the second leading cause of TBI-related hospitalizations across 
age groups (CDC, 2020). Children under the age of eight years old are mainly injured by 
falls, abuse-related injuries, motor vehicle accidents, and transportation-related accidents 




contribute to the high prevalence during childhood and adolescence (Agarwal, MD et al., 
2021). Other risk factors across age groups may include male gender and participation in 
sports (Agarwal, MD et al., 2021). 
Pediatric Traumatic Brain Injury 
According to the CDC, approximately 475,000 children ages 14 years and under 
sustain TBI annually, with up to 90% sustaining mild injury (Araki et al., 2017). As the 
leading cause of death and disability in children, injury patterns in pediatric patients are 
distinctively different from those observed in adults (Araki et al., 2017). Even within the 
pediatric population, age-related anatomical and physiological differences contribute to 
varied injury patterns (Araki et al., 2017). For example, as age decreases, the thickness of 
the scalp also decreases, thereby reducing the scalp’s protective ability (Araki et al., 
2017). In infants specifically, the skull plasticity and open sutures allow for movement 
during trauma, leading to stretching that can injure brain parenchyma (Araki et al., 2017). 
Other differences in children include weak neck musculature, increased head size, and 
lack of myelin (Araki et al., 2017).  
Between 2007 and 2014, there was a 60% increase in concussion, a mild TBI, in the 
general population, with pediatric and adolescent patients accounting for the majority of 
this increase (Smith et al., 2019). Approximately 1.9 million individuals under 18 years 
old sustain a sports-related concussion each year, with rates of pediatric sports-related 
and non-sports-related concussion being highest in individuals between the ages of 15 
and 19 years old (Smith et al., 2019). While symptoms of concussion usually resolve 
within one month of injury, up to 30% of pediatric patients have symptoms extending 




homeostasis that may contribute to secondary injury processes (Smith et al., 2019). 
Impairment in cerebrovascular autoregulation can leave the brain vulnerable to post-
traumatic hyperemia and ischemia, which can contribute to neurologic dysfunction.  
(Smith et al., 2019). Given the prevalence of TBI in the pediatric population and the stark 
anatomical and physiological differences, identifying the consequences of secondary 
injury processes is vital. 
Sport-Related Concussion 
The CDC estimates between 1.6 million and 3.8 million sports-related TBIs occur 
each year (CDC, 2020). Actual numbers may be higher, as many individuals sustaining 
mild TBI do not seek medical attention (McKeithan et al., 2019). Concussions are 
considered mild TBIs characterized by diffuse injury that alters mental status, while 
sport-related concussion (SRC) refers specifically to TBI induced by biomechanical 
forces (Agarwal, MD et al., 2021). These sport-related injuries include sub-concussive 
injures that are usually produced by acceleration-deceleration forces (VanItallie 2019). 
SRC and mild TBI are often used synonymously, but an important distinction should be 
differentiated. Both SRC and mTBI overlap on the Glasgow Coma Scale, but any 
condition with positive neuroimaging is no longer categorized as a concussion and is 
instead considered a mTBI (McKeithan et al., 2019). Sports such as American football, 
soccer, boxing, rugby, and cheerleading frequently contribute to concussion rates, as the 
forces involved can subject the brain to secondary injury processes (VanItallie 2019). 
While most symptoms associated with SRC result from a functional disturbance rather 
than a structural disturbance, neuropathological changes may occur (Agarwal, MD et al., 




evidence does not show a causal relationship between SRC and neuropathological 
sequelae (McKeithan et al., 2019). Of the associations found between SRC and long-term 
cognitive changes, one of the strongest predictors in determining the duration of 
persistent symptoms is the severity of symptoms associated with the initial injury 
(McKeithan et al., 2019). Another factor contributing to long-term cognitive defects is 
prior concussion or TBI history (Oleksii et al., 2019). Some studies have found a 
cumulative effect in patients sustaining repetitive head injuries (Lasry et al., 2017). 
Approximately 5.5% of patients experience recurrent TBI within one year of the index 
case, with even more experiencing recurrence after one year (Lasry et al., 2017). 
Furthermore, approximately 16% of youth experience recurrent injury within 2 years 
(Eyolfson et al., 2020). Given the frequency and increasing incidence of mild TBI and 
recurrent injury, exploration of the long-term consequences is critical.  
Post-Traumatic Epilepsy 
 PTE, a common consequence of TBI, is a recurrent seizure disorder secondary to 
trauma to the brain (Keith & Huang, 2019). PTE can contribute to progressive and long-
term neurodegenerative and neurocognitive symptoms in adults and children (Webster et 
al., 2017). While immediate and early seizures can occur within one week of injury, a 
diagnosis of PTE is made after the observation of two or more unprovoked seizures 
occurring later than one week after injury (Park & Chugani 2015). Most cases of PTE are 
resistant to existing anti-epileptic drugs, making treatment extremely difficult (Webster et 
al., 2017).  While the exact etiology of PTE remains unknown, many secondary 
neurobiological processes are thought to be involved (Keith & Huang, 2019). Moreover, 




inducing epileptogenesis, the process by which epilepsy develops (Webster et al., 2017). 
Epilepsy occurs when a normally functioning brain becomes abnormally electrically 
activated, decreasing the threshold for spontaneous, recurrent seizures (Webster et al., 
2017). Along with age; injury type, severity, and individual factors also contribute to the 
development and pathogenesis of PTE (Webster et al., 2017). In PTE development, there 
is an initial trigger, a latency period, and the onset of spontaneous seizures (Webster et 
al., 2017). The latency period is of particular interest, as this is the time when secondary 
neurological processes leading to PTE occur (Webster et al., 2017). Following TBI, the 
latency period may last weeks or even years (Webster et al., 2017).   
The incidence of PTE following TBI ranges greatly, as estimates range from 4% to 
53% (Webster et al., 2017). Patients with more severe injury and younger age have the 
highest risk for developing PTE (Webster et al., 2017). For example, studies show that 
children under the age of five-years-old are at the highest risk for developing PTE, in 
comparison to older children and adults (Park & Chugani 2015). Most PTE research 
investigates focal or penetrating injuries, with little research focused on mild or diffuse 
injuries (Oleksii et al., 2019). Only about 10% of TBI patients experience focal injury, as 
most TBIs are a combination of focal and diffuse injuries (Oleksii et al., 2019). 
Difficulties with diagnosis and follow-up are potential causes for the wide reported range 
of PTE and lack of research into diffuse injury (Webster et al., 2017).  
Further consideration should be given to the pediatric population, as age-related 
differences may drastically alter the characteristics of PTE. Research shows that seizures 
are particularly harmful during brain development and can cause permanent neurological 




injury, the long-term consequences of PTE on the developing brain should be further 
explored. 
Neuroinflammation in PTE 
Inflammation is a physiological process that protects against foreign pathogens, and 
the term “neuroinflammation” describes the inflammatory process occurring in the CNS 
(Sharma et al., 2019). The main components of the cerebral inflammatory response 
include the release of inflammatory factors like cytokines, microglial and astrocytic 
activation, edema, blood-brain barrier (BBB) disruption, and the recruitment of blood-
derived leukocytes (Webster et al., 2017). The period after TBI in which secondary injury 
processes are initiated is critical in the development of epilepsy and research has shown 
that inflammatory molecules may mediate early seizures (Webster et al., 2017). Seizures, 
themselves, can also further increase the presence of inflammatory mediators by 
upregulating inflammatory genes (Webster et al., 2017). Chronic overexpression of pro-
inflammatory molecules may alter neuronal networks and ultimately reduce seizure 
threshold (Webster et al., 2017). When examining the brain tissue of epileptic patients, 
researchers found elevated levels of pro-inflammatory cytokines and high mobility group 
box-1 (HMGB-1) protein in neurons and glia (Webster et al., 2017). When the infiltration 
of microglia and monocytes was inhibited, an electroconvulsive shock-induced seizure 
was reversed (Webster et al., 2017).  
Neuroinflammatory Cytokines 
The interleukin-1 (IL-1) family of cytokines, including IL-1ß, are important 




involved in focal and diffuse brain injuries, as it regulates edema, leukocyte recruitment, 
the release of neurotoxic mediators promoting glial activation, and disruption of the BBB 
(Sharma et al., 2019). Both adult and pediatric patients suffering from severe TBI show 
an increase in IL-1ß, which is associated with worse outcomes (Webster et al., 2017). In 
rodent models of TBI, both interference with IL-1ß synthesis and the use of IL-1 receptor 
antagonists demonstrate neuroprotective qualities (Sharma et al., 2019). The use of an IL-
1ß neutralizing antibody was also found to reduce some of the effects of TBI, such as 
cerebral edema, microglial activation, and cognitive deficits (Webster et al., 2017). Since 
interference with IL-1ß synthesis, IL-1ß neutralizing antibody, and IL-1 receptor 
antagonists showed similar results, it can be concluded that the IL-1 family of cytokines 
mediates some of the secondary injury processes following TBI (Webster et al., 2017). 
Research has suggested ictogenic properties of IL-1ß, as elevated serum and CSF 
levels are associated with several epileptic conditions (Sharma et al., 2019). It is thought 
that IL-1ß may interfere with gamma-Aminobutyric acid (GABA)-mediated 
neurotransmission, inhibit glutamate uptake by astrocytes, and regulate neuronal 
excitability via 𝛼-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-
methyl-D-aspartate (NMDA) receptors, which are involved in glutamate-mediated 
neurotransmission (Perron et al., 2001). In the specific case of PTE, antagonism of the 
IL-1 receptor in young TBI mice resulted in decreased susceptibility for provoked and 
unprovoked seizures, as well as decreased cortical tissue loss (Sharma et al., 2019). The 
same experimental model also showed that inhibition of IL-1ß synthesis resulted in 
reduced seizure activity, suggesting IL-1ß involvement in the initiation of post-traumatic 




Tumor necrosis factor-alpha (TNF-𝛼), considered a pro-inflammatory cytokine, 
may also be involved in the development of PTE via pro- and anti-inflammatory 
mechanisms (Webster et al., 2017). While elevated TNF-𝛼 levels lead to leukocyte 
infiltration, neurodegeneration, and BBB damage, the absence of this cytokine or its 
receptor was associated with increased neurodegeneration, longer recovery time, and 
even mortality in mice (Sharma et al., 2019). This suggests that while TNF-α can increase 
CNS damage, it can also be neuroprotective in the later stages of the inflammatory 
response, occurring weeks after TBI (Webster et al., 2017). TNF-𝛼 also displays dual 
functionality in the context of seizures, being both pro- and anti-convulsive (Sharma et 
al., 2019). There is, however, a discrepancy in describing the role of TNF-𝛼. Some 
studies concluded that elevated TNF-𝛼 levels resulted in shorter seizures, and lack of the 
TNF-𝛼 receptor led to longer seizures (Sharma et al., 2019). Other studies have shown 
the opposite: elevated TNF-𝛼 resulted in seizures and early death (Sharma et al., 2019). 
This contrasting evidence may be attributed to two different TNF-𝛼 receptors, TNF-𝛼-R1 
(p55) and TNF-𝛼-R2 (p75) (Sharma et al., 2019). Research showed that mice lacking the 
p75 receptor had increased epileptic activity, while mice lacking the p55 receptor showed 
decreased epileptic activity (Sharma et al., 2019). Considering PTE specifically, the role 
of TNF-𝛼 has not been defined (Sharma et al., 2019).  
Other cytokines and proteins worth mentioning in the context of PTE include IL-
6, HMGB-1, and IL-10 (Sharma et al., 2019). IL-6 is expressed by many cells in the 
CNS, including astrocytes and microglia (Sharma et al., 2019). Similar to TNF-𝛼, IL-6 




the inflammatory response but can also inhibit the production of TNF-𝛼, reduce NMDA 
toxicity, and promote neuronal differentiation and survival (Sharma et al., 2019). Of the 
inflammatory cytokines IL-6 often presents in the highest concentrations following TBI 
and is considered to be ictogenic, correlating with the severity of epileptic seizures 
(Sharma et al., 2019). Clinical findings have shown adults with tonic-clonic seizures had 
a corresponding increase in IL-6 and IL-1 receptors (Webster et al., 2017). HMGB-1 is a 
DNA-binding protein that serves as a damage-associated molecular pattern following 
tissue injury (Sharma et al., 2019). Suspected in neurodegeneration, edema, TBI, and 
epilepsy, HMGB-1 promotes the immune response and the release of pro-inflammatory 
compounds (Sharma et al., 2019). Experimental animal models showed that inhibition of 
HMGB-1 reduced the development of acquired epilepsies (Sharma et al., 2019). HMGB-
1 may interact with NMDA receptors and IL-1ß to result in abnormal electrical activity 
(Sharma et al., 2019). The cytokine IL-10 is considered anti-inflammatory, as it inhibits 
the actions of many pro-inflammatory molecules, like IL-1ß and TNF-𝛼 (Sharma et al., 
2019). Therefore, IL-10 can regulate processes like leukocyte infiltration and glial cell 
activation, thus preventing CNS damage (Sharma et al., 2019). Several animal studies 
have shown the anti-seizure effect of IL-10 in cases of hypoxia- and hyperthermia-
induced seizures (Sharma et al., 2019).  
While not explored in detail in this review, several other cytokines and proteins 
have been implicated concerning PTE, including but not limited to transforming growth 
factor-alpha (TGF-𝛼), ciliary neurotrophic factor (CNTF), and leukemia inhibitory factor 




dual role in neuroinflammation. Future studies should seek to identify the factors 
influencing the effects each cytokine may have.  
Reactive Gliosis 
Astrocytes are involved in maintaining homeostasis in the CNS (Pekny & Pekna, 
2016). Astrocytes communicate with neurons and the endothelium to influence processes 
like the regulation of blood flow and BBB function (Pekny & Pekna, 2016). Additionally, 
astrocytes are involved in the formation and function of neuronal synapses (Pekny & 
Pekna, 2016). Protoplasmic astrocytes are found in gray matter and may regulate up to 2 
million neuronal synapses (Pekny & Pekna, 2016). Astrocytes are connected via gap 
junctions and form an interconnected network, allowing communication between 
neighboring cells (Pekny & Pekna, 2016). During neurotrauma, including epilepsy, 
stroke, or neurodegenerative disease, astrocytes respond by a defensive process termed 
reactive gliosis (Pekny & Pekna, 2016). During injury, astrocytes respond to changes in 
gene expression resulting in alterations in astrocyte shape and function (Pekny & Pekna, 
2016). The most severe form of reactive gliosis leads to the formation of a glial scar that 
is responsible for creating a seal around injured brain tissue, thus protecting the 
surrounding healthy tissue (Pekny & Pekna, 2016).  
 According to recent studies, the elimination of a population of reactive astrocytes 
can lead to increased neurodegeneration and BBB deficits, suggesting the neuroprotective 
effects of gliosis (Pekny & Pekna, 2016). Several cytokines, including transforming 
growth factor-alpha (TGF-𝛼), ciliary neurotrophic factor (CNTF), leukemia inhibitory 




While mediating tissue repair, astrocytes can sometimes over-produce cytokines and alter 
BBB and neuronal function (Webster et al., 2017). This may lead to an inflammatory 
response and a hyperexcited environment conducive to seizure development (Webster et 
al., 2017). In the case of spinal cord injury, inhibition of transcription of these cytokines 
results in inhibited astrocyte migration, increased migration of inflammatory cells into 
injured brain tissue, and larger lesions (Pekny & Pekna, 2016). On the other hand, 
allowing the transcription of cytokines, such as IL-6, resulted in increased astrocyte 
migration, smaller lesions, and better recovery following spinal cord injury (Pekny & 
Pekna, 2016). Importantly, these results relate to fibrous astrocytes in white matter and 
have not been tested in relation to protoplasmic astrocytes in gray matter (Pekny & 
Pekna, 2016).  
 The astrocyte intermediate filament proteins glial fibrillary acidic protein (GFAP) 
and vimentin (Vim) are both known to be involved in reactive gliosis and glial scar 
formation (Pekny & Pekna, 2016). GFAP and Vim are upregulated during reactive gliosis 
(Pekny & Pekna, 2016). When examined in mice, the elimination of both GFAP and Vim 
led to reduced gliosis and glial scar formation, which resulted in slower wound healing, 
increased loss of neuronal synapses, and lower resistance of the CNS to mechanical stress 
(Pekny & Pekna, 2016). These results demonstrate the important role of astrocytic 
intermediate filament proteins in limiting the effects of neurotrauma. It is also important 
to note that adolescent mice had lower levels of reactive gliosis following brain injury 
(Pekny & Pekna, 2016). Even in the absence of GFAP and Vim, when younger mice 
underwent hypoxic-ischemia normal size injury areas resulted (Pekny & Pekna, 2016). 




but also highlights the potential stark differences between adult and pediatric TBI (Pekny 
& Pekna, 2016). Lastly, the astrocytic intermediate filament network is connected to the 
efficiency of glutamate transport and astrocyte gap junctional communication, both of 
which have important implications in the development of epilepsy (Pekny & Pekna, 
2016).  
Diagnosis and Management of Traumatic Brain Injury 
 TBI can produce a combination of diffuse injury, focal injury, and various 
secondary processes (Thelin et al., 2019). Current diagnostic criteria involve clinical 
examination and evaluation using the Glasgow Coma Scale. In cases of mild TBI, like 
SRC, clinical diagnoses depend largely on self-reported information provided by the 
patient (Meier et al., 2020). With the subjectivity of current TBI diagnostic practices, 
more objective and universal diagnostic techniques are needed. Although there are 
objective criteria in place for PTE diagnosis, guidelines should be established to identify 
at-risk patients and prevent epilepsy development.  
Biomarkers 
 Given the challenges and cost burden of screening for TBI and epilepsy, recent 
research has focused on the potential use of biomarkers as a means of diagnosis (Thelin 
et al., 2019). A biomarker is an objectively measurable indicator of a biological process 
(Liang et al., 2019). To be considered useful in the context of neurological processes, a 
biomarker must exhibit specific qualities, for example, it should be low or undetectable in 
serum, it should exist in the CNS, and it should be detected in brain injury (Liang et al., 




predict the injury severity, and help determine which patients may need neuroimaging or 
further intervention (Thelin et al., 2019). In addition to initial TBI diagnosis and 
classification, biomarkers can also be used to monitor emerging secondary injury 
processes that may lead to long-term consequences, such as PTE (Thelin et al., 2019). 
Serum protein biomarkers associated with TBI include S100 calcium-binding protein B 
(S100B), GFAP, ubiquitin carboxy-terminal hydrolase 1 (UCH-L1), neurofilament light 
(NF-L), and tau (Thelin et al., 2019). All of these biomarkers were positively correlated 
with TBI severity (Thelin et al., 2019).  
Biomarkers for epilepsy should identify the presence, development, severity, 
progression, or localization of abnormal electrical activity (Liang et al., 2019). 
Biomarkers are of great importance when considering patients with seizures that do not 
respond to typical anti-epileptic treatments (Liang et al., 2019). Various biomarkers have 
been suspected concerning PTE, including protein and genetic markers (Pitkänen et al., 
2020). Since biomarkers associated with processes such as neuroinflammation, oxidative 
stress, and metabolic dysfunction, which may occur following TBI, potentially correlate 
with the development of epilepsy, research should further explore potential connections.  
(Liang et al., 2019). 
TBI Biomarkers 
The S100B protein is found in the CNS, melanocytes, chondrocytes, and adipocytes 
(Liang et al., 2019). It has many functions, including regulation of cell cycle progression, 
stimulation of cell proliferation and migration, and inhibition of apoptosis and 




is described as a robust predictor of outcome in TBI (Thelin et al., 2019). Elevated S100B 
in serum may be a sign of damaged neurons or glial cells or even the result of secondary 
brain injury (Shulte et al., 2014). Because of this, S100B is a part of the Scandinavian 
Neurotrauma Guidelines to reduce the number of unnecessary computed tomography 
(CT) scans in mild TBI patients (Thelin et al., 2019). S100B has also been implicated in 
the management of SRC, a mild form of TBI (Shulte et al., 2014). S100B increases in 
concentration following cerebral insult, but the protein usually remains in the CNS due to 
its size and lack of a transporter to cross the blood-brain barrier (Shulte et al., 2014). 
Studies have suggested that finding S100B in peripheral circulation indicates damage to 
the endothelial tight junctions of the BBB during mTBI (Shulte et al., 2014). It is also 
important to consider extracranial sources that contribute to peripheral increases in 
concentration (Shulte et al., 2014). Researchers reported significant increases in 
peripheral protein levels following competitive and vigorous physical activity without 
head injury (Shulte et al., 2014). Before this biomarker can be used, reference values 
must be determined, and the influence of extracranial sources evaluated (Shulte et al., 
2014). 
While using the S100B protein in TBI management is promising, GFAP may 
provide more accurate information (McCrea et al., 2020). GFAP is an astrocytic 
intermediate filament protein involved in the regulation of neuronal synapses and is often 
associated with increased intracranial pressure and axonal injury (Mahan et al., 2019). 
Upregulation of GFAP following cerebral insult, due to damage-induced hypertrophy in 
glial cells, is associated with TBI (Mahan et al., 2019). Additionally, GFAP-breakdown 




et al., 2019). In cases of concussed athletes, serum GFAP concentrations were 
significantly increased during the acute post-injury period and 24-48 hours post-injury 
when compared to controls (McCrea et al., 2020). GFAP levels of concussed athletes 
who lost consciousness (LOC) and those who developed post-traumatic amnesia (PTA) 
were even further increased when compared to concussed athletes with no LOC or PTA 
(McCrea et al., 2020).  
Through ubiquitination, the enzyme UCH-L1 maintains neuronal health by 
removing abnormal proteins and preventing secondary brain injury (McCrea et al., 2020). 
Studies report increased serum UCH-L1 in cases of TBI. (Mahan et al., 2019). When 
compared to control groups, athletes presenting with concussion had significant serum 
increases in UCH-L1 levels during the acute post-injury period (McCrea et al., 2020). By 
24-48 hours post-injury, UCH-L1 levels were similar in the concussion and control 
groups (McCrea et al., 2020). In contrast to other protein biomarkers, UCH-L1 levels 
were significantly lower in concussed athletes at the asymptomatic time point (McCrea et 
al., 2020). The United States Food and Drug Administration approved both GFAP and 
UCH-L1 for clinical use in determining whether or not an intracranial injury is present 
(McCrea et al., 2020). If intracranial injury is predicted, future studies should aim to 
identify levels of GFAP and UCH-L1 that may correspond with neurological deficits.  
Some of the other serum biomarkers indicated in TBI management are neuron-
specific enolase (NSE), NF-L, and tau. Similar to UCH-L1, concussed athletes showed 
significant increases in tau during the acute post-injury period, while at 24-48 hours post-
injury, levels were significantly lower than control groups (McCrea et al., 2020). While 




al., 2019). Notably, all biomarkers associated with TBI, except NF-L, decreased over 
time following injury (Thelin et al., 2019). Since NF-L levels continued to increase in the 
weeks after injury, this biomarker may be useful in evaluating TBI in later stages (Thelin 
et al., 2019). Additionally, the long-lasting effects of NF-L should be explored in relation 
to sequelae associated with TBI (Thelin et al., 2019). 
PTE Biomarkers 
Several protein biomarkers have been used to characterize patients with epilepsy 
in comparison to controls with convulsive seizures initiated by other events (Pitkänen et 
al., 2020). Examples of protein markers with this ability are soluble intercellular adhesion 
molecule 5 (sICAM-5), the IL-6 cytokine, and S100B, which distinguishes between 
patients with focal seizures and controls (Pitkänen et al., 2020). Studies also found that 
patients with epilepsy had significantly elevated serum levels of S100B (Liang et al., 
2019). Additionally, an animal model demonstrated that an oral anti-epileptic reagent 
reduced glial cell proliferation and S100B proteins (Liang et al., 2019). This decrease in 
S100B correlated with reduced epileptic seizures (Liang et al., 2019). The proteins GFAP 
and UCH-L1 are associated with initial TBI severity, and both differentiated epileptic 
seizures from psychogenic nonepileptic seizures (Pitkänen et al., 2020). Complement 
components such as C3, C4, and C1 inhibitor also identify epileptic patients (Pitkänen et 
al., 2020). Proteins HMGB-1 and IL-1ß, both associated with TBI, predicted seizure 
frequency (Pitkänen et al., 2020). The tau protein is known to correlate to longer recovery 
following mild TBI, and studies have shown increased tau levels following seizures and 
status epilepticus (Pitkänen et al., 2020). This increase could be both indicative and 




Genetic biomarkers may offer insight into genetic mutations related to disease 
development and severity (Pitkänen et al., 2020). In TBI patients, genetic biomarkers 
may allow providers to identify patients with an increased risk for the development of 
PTE (Pitkänen et al., 2020). Early identification of these patients may lead to trials of 
antiepileptic agents, decreasing the occurrence of PTE in patients with known genetic 
variants (Pitkänen et al., 2020). Several potential genetic markers have been identified, 
including GAD1, SLC1A1, and SLC1A3 (Pitkänen et al., 2020). The GAD1 gene 
encodes the enzyme glutamic acid decarboxylase 1, which is responsible for the synthesis 
of the inhibitory neurotransmitter GABA (Pitkänen et al., 2020). Genetic variants in the 
GAD1 gene were associated with an increased risk of developing post-traumatic seizures 
(Pitkänen et al., 2020). The chief excitatory neurotransmitter is glutamate, and mutations 
in the glutamate transporter genes SLC1A1 and SLC1A3 were also associated with 
increased post-traumatic seizure risk (Pitkänen et al., 2020). Lastly, mutations in the IL-1 
gene, coding for the cytokine IL-1ß, were also associated with an increased risk of PTE 
(Pitkänen et al., 2020).   
Common serum biomarkers between TBI and PTE include GFAP, IL-1, HMGB-
1, UCH-L1, tau, and S100B (Pitkänen et al., 2020). While each marker can be associated 
with the processes underlying TBI, more research is needed to establish relationships 
with epileptogenesis. Future studies should also aim to qualitatively and quantitatively 








To complete this literature review, the search engine PubMed was used. Search 
criteria included terms such as traumatic brain injury, epidemiology, post-traumatic 
epilepsy, mild TBI, diffuse TBI, sport-related concussion, neuroinflammation, astrocytes, 
gliosis, and biomarkers. Information from the Centers for Disease Control and Prevention 
and the American Association of Neurological Surgeons was also examined. Results 
were narrowed down to include literature from the years 2015-2021 and relevant 




















RESULTS AND DISCUSSION 
 
During the coronavirus 2019 (COVID-19) pandemic, consideration should be 
given to the impact of the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-
CoV-2) virus on TBI patients. Early research shows that the virus can enter the CNS, 
either via the ACE2 receptor on olfactory neurons or by infecting immune cells with the 
ACE2 receptor that eventually cross the BBB (Nikbakht et al., 2020). Once in the CNS, 
neurological symptoms, including epilepsy, may be mediated by the upregulation of pro-
inflammatory cytokines by astrocytes and microglia (Nikbakht et al., 2020). 
Neuropathological changes in infected patients included microglial activation and 
astrogliosis (Lou et al., 2021). This provides further evidence for the connection between 
neuroinflammation and epileptogenesis. Given the increased risk of PTE under normal 
circumstances, TBI patients may be particularly vulnerable to neurologic dysfunction if 
infected with the COVID-19 virus. Further information is needed regarding the 
mechanisms of SARS-CoV-2-induced epilepsy, especially in TBI patients.  
To conclude, there are many factors to consider when exploring the relationship 
between TBI and PTE. Diagnostic biomarkers may offer insight into secondary injury 
processes and provide a preventative advantage. The interplay of several 
neuropathophysiological processes and mediators may contribute to PTE development. 
Further research should seek to establish causal relationships and identify targets for 
therapeutic intervention. With most cases of PTE being resistant to existing treatments, it 






1. Centers for Disease Control and Prevention. (2020, August 28). Traumatic Brain 
Injury / Concussion. Centers for Disease Control and Prevention. 
https://www.cdc.gov/traumaticbraininjury/index.html.  
2. Webster, K. M., Sun, M., Crack, P., O'Brien, T. J., Shultz, S. R., & Semple, B. D. 
(2017). Inflammation in epileptogenesis after traumatic brain injury. Journal of 
Neuroinflammation, 14(1), 10. https://doi.org/10.1186/s12974-016-0786-1  
3. Mahan, M. Y., Thorpe, M., Ahmadi, A., Abdallah, T., Casey, H., Sturtevant, D., 
Judge-Yoakam, S., Hoover, C., Rafter, D., Miner, J., Richardson, C., & Samadani, U. 
(2019). Glial fibrillary acidic protein (GFAP) outperforms S100 calcium-binding 
protein B (S100B) and ubiquitin C-terminal hydrolase L1 (UCH-L1) as predictor for 
positive computed tomography of the head in trauma subjects. World 
Neurosurgery, 128, e434-e444. https://doi.org/10.1016/j.wneu.2019.04.170 
4. Meier, T. B., Huber, D. L., Bohorquez-Montoya, L., Nitta, M. E., Savitz, J., Teague, 
T. K., Bazarian, J. J., Hayes, R. L., Nelson, L. D., & McCrea, M. A. (2020). A 
prospective study of acute blood-based biomarkers for sport-related 
concussion. Annals of Neurology, 87(6), 907-920. https://doi.org/10.1002/ana.25725 
5. Thelin, E., Al Nimer, F., Frostell, A., Zetterberg, H., Blennow, K., Nyström, H., 
Svensson, M., Bellander, B., Piehl, F., & Nelson, D. W. (2019). A serum protein 




injury. Journal of Neurotrauma, 36(20), 2850-
2862. https://doi.org/10.1089/neu.2019.6375 
6. Maas, A. I. R., Menon, D. K., Adelson, P. D., Andelic, N., Bell, M. J., Belli, A., 
Bragge, P., Brazinova, A., Büki, A., Chesnut, R. M., Citerio, G., Coburn, M., Cooper, 
D. J., Crowder, A. T., Czeiter, E., Czosnyka, M., Diaz-Arrastia, R., Dreier, J. P., 
Duhaime, A., . . . Zumbo, F. (2017). Traumatic brain injury: Integrated approaches to 
improve prevention, clinical care, and research. The Lancet Neurology, 16(12), 987-
1048. https://doi.org/10.1016/S1474-4422(17)30371-X 
7. Araki, T., Yokota, H., & Morita, A. (2017). Pediatric traumatic brain injury: 
Characteristic features, diagnosis, and management. Neurologia Medico-
Chirurgica, 57(2), 82-93. https://doi.org/10.2176/nmc.ra.2016-0191 
8. Agarwal, MD, N., Thakkar, R., & MD, FAANS, K. T. (2021). Sports-related Head 
Injury. AANS. https://www.aans.org/Patients/Neurosurgical-Conditions-and-
Treatments/Sports-related-Head-Injury.  
9. Smith, E. B., Lee, J. K., Vavilala, M. S., & Lee, S. A. (2019). Pediatric traumatic 
brain injury and associated topics. Anesthesiology Clinics, 37(1), 119-
134. https://doi.org/10.1016/j.anclin.2018.10.002 
10. McKeithan, L., Hibshman, N., Yengo-Kahn, A. M., Solomon, G. S., & Zuckerman, S. 
L. (2019). Sport-related concussion: Evaluation, treatment, and future 




11. VanItallie, T. B. (2019). Traumatic brain injury (TBI) in collision sports: Possible 
mechanisms of transformation into chronic traumatic encephalopathy 
(CTE). Metabolism, 100, 153943. https://doi.org/10.1016/j.metabol.2019.07.007 
12. Shandra, Oleksii et al. “Repetitive Diffuse Mild Traumatic Brain Injury Causes an 
Atypical Astrocyte Response and Spontaneous Recurrent Seizures.” The Journal of 
neuroscience : the official journal of the Society for Neurosciencevol. 39,10 (2019): 
1944-1963. doi:10.1523/JNEUROSCI.1067-18.2018 
13. Lasry, O., Liu, E. Y., Powell, G. A., Ruel-Laliberté, J., Marcoux, J., & Buckeridge, 
D. L. (2017). Epidemiology of recurrent traumatic brain injury in the general 
population: A systematic review. Neurology, 89(21), 2198–2209. 
https://doi.org/10.1212/WNL.0000000000004671 
14. Eyolfson, E., Khan, A., Mychasiuk, R., & Lohman, A. W. (2020). Microglia 
dynamics in adolescent traumatic brain injury. Journal of Neuroinflammation, 17(1), 
326. https://doi.org/10.1186/s12974-020-01994-z 
15. Keith, K. A., & Huang, J. H. (2019). Animal Models of Post-Traumatic 
Epilepsy. Diagnostics (Basel, Switzerland), 10(1), 4. 
https://doi.org/10.3390/diagnostics10010004 
16. Park, J. T., & Chugani, H. T. (2015). Post-traumatic epilepsy in children-experience 
from a tertiary referral center. Pediatric Neurology, 52(2), 174-
181. https://doi.org/10.1016/j.pediatrneurol.2014.09.013 
17. Sharma, R., Leung, W. L., Zamani, A., O'Brien, T. J., Casillas Espinosa, P. M., & 




Pathophysiology and tractable therapeutic targets. Brain 
Sciences, 9(11)https://doi.org/10.3390/brainsci9110318 
18. Perron, A. D., Brady, W. J., & Huff, J. S. (2001). Concussive convulsions: 
Emergency department assessment and management of a frequently misunderstood 
entity. Academic Emergency Medicine: Official Journal of the Society for Academic 
Emergency Medicine, 8(3), 296-298. https://doi.org/10.1111/j.1553-
2712.2001.tb01312.x 
19. Pekny, M., & Pekna, M. (2016). Reactive gliosis in the pathogenesis of CNS 
diseases. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of 
Disease, 1862(3), 483-491. https://doi.org/10.1016/j.bbadis.2015.11.014 
20. Liang, K., Mu, R., Liu, Y., Jiang, D., Jia, T., & Huang, Y. (2019). Increased serum 
S100B levels in patients with epilepsy: A systematic review and meta-analysis 
study. Frontiers in Neuroscience, 13, 456. https://doi.org/10.3389/fnins.2019.00456 
21. Pitkänen, A., Paananen, T., Kyyriäinen, J., Das Gupta, S., Heiskanen, M., Vuokila, 
N., Bañuelos-Cabrera, I., Lapinlampi, N., Kajevu, N., Andrade, P., Ciszek, R., Lara-
Valderrábano, L., Ekolle Ndode-Ekane, X., & Puhakka, N. (2020). Biomarkers for 
posttraumatic epilepsy. Epilepsy & Behavior, , 
107080. https://doi.org/10.1016/j.yebeh.2020.107080 
22. Schulte, S., Podlog, L. W., Hamson-Utley, J. J., Strathmann, F. G., & Strüder, H. K. 
(2014). A systematic review of the biomarker S100B: Implications for sport-related 





23. McCrea, M., Broglio, S. P., McAllister, T. W., Gill, J., Giza, C. C., Huber, D. L., 
Harezlak, J., Cameron, K. L., Houston, M. N., McGinty, G., Jackson, J. C., 
Guskiewicz, K., Mihalik, J., Brooks, M. A., Duma, S., Rowson, S., Nelson, L. D., 
Pasquina, P., Meier, T. B., . . . DiFiori, J. (2020). Association of blood biomarkers 
with acute sport-related concussion in collegiate athletes: Findings from the NCAA 
and department of defense CARE consortium. JAMA Network Open, 3(1), 
e1919771. https://doi.org/10.1001/jamanetworkopen.2019.19771 
24. Nikbakht, F., Mohammadkhanizadeh, A., & Mohammadi, E. (2020). How does the 
COVID-19 cause seizure and epilepsy in patients? the potential mechanisms. Multiple 
Sclerosis and Related Disorders, 46,  102535. 
https://doi.org/10.1016/j.msard.2020.102535 
25.  Lou, J. J., Movassaghi, M., Gordy, D., Olson, M. G., Zhang, T., Khurana, M. S., 
Chen, Z., Perez-Rosendahl, M., Thammachantha, S., Singer, E. J., Magaki, S. D., 
Vinters, H. V., & Yong, W. H. (2021). Neuropathology of COVID-  19 (neuro-
COVID): Clinicopathological update. Free Neuropathology, 2 
https://doi.org/10.17879/freeneuropathology-2021-2993 
 
